Melatonin for Kids: Is It Safe?

If you’ve spent any time talking to other parents about sleep, you’ve probably heard about melatonin. One person swears by it. Someone else warns against it. And if your child is struggling to fall asleep, it can be hard to know what to believe.

Melatonin is widely available, often marketed as a “natural” sleep aid, and increasingly used to help kids of all ages. But it may not be the right solution. The key is knowing when it makes sense, when it doesn’t, and how to make it work best as part of a bigger sleep plan.

What is melatonin?

Melatonin is a hormone the body produces naturally to regulate sleep. As it gets dark, the brain releases melatonin to signal that it’s time to wind down. Light exposure at night — especially blue light from screens — can disrupt the body’s natural rhythm so you don’t feel sleepy even when it’s bedtime.

“Melatonin supplements can help facilitate that circadian rhythm, that 24-hour sleep cycle,” says Rohn Nahmias, DO, a child and adolescent psychiatrist at the Child Mind Institute. Because it’s sold over the counter, melatonin seems to be harmless. In practice, clinicians are much more cautious. While they tend to consider it relatively low risk, with few side effects, they still don’t view it as something to take casually or indefinitely.

That’s because there are real gaps in what we know about melatonin — especially when kids take it regularly over long periods. “The longest study was about four years, and they did not find any issues,” says Judith Owens, MD, MPH, a pediatric sleep expert and professor of neurology at Harvard Medical School. “But the data are very limited in subject numbers and long-term follow-up.”

So, the question parents often ask — is melatonin safe for kids? — doesn’t have a simple yes or no answer. The more useful question may be whether melatonin is right for your kid and what guidelines should you follow if you’re going to give it to them.  

That’s why it’s especially important to consult your child’s pediatrician or tell them if you’ve already started your child on melatonin. “Because melatonin is over the counter, families often forget to mention it,” says Dr. Nahmias. But doctors need to know about supplements, especially if a child is on other medications or has additional health concerns.

Melatonin can be helpful in the right situations, but using it without looking deeper can be “kind of slapping a Band-Aid onto a problem,” Dr. Nahmias says. In his practice, he always wants to rule out anxiety, mood concerns, or a medical issue that may be impacting sleep (such as snoring, breathing problems, or pain) before introducing something new like melatonin.

When melatonin can help

Melatonin is most useful when the issue is falling asleep, not staying asleep. For example, if your child has persistent trouble falling asleep — not just occasional bedtime resistance — and you have already tried using behavioral strategies.

The immediate-release melatonin sold in the United States is primarily helpful for sleep onset. (A prolonged-release form approved in the UK and EU may help with staying asleep, but it’s not available here.) Melatonin can also help with circadian rhythm issues like delayed sleep-wake phase disorder, when a child or teen’s natural sleep and wake times are much later than their schedule allows. “That is the other real indication for melatonin,” Dr. Owens says.

How to use melatonin thoughtfully

If melatonin does make sense for your child, experts agree: Start low and go slow. Dr. Nahmias recommends beginning with 1 to 2 milligrams for kids four and up and increasing the dose only if needed — up to 3 milligrams for kids ages 6–10. Many children respond well to low amounts. More than 5 milligrams, he says, isn’t much more effective and is more likely to cause side effects like grogginess or irritability. Dr. Owens emphasizes a similarly cautious approach: Use the lowest effective dose, monitor whether it’s actually helping, and reassess regularly rather than letting it quietly become an open-ended routine.

Dr. Nahmias recommends using melatonin in “clusters” — short, purposeful stretches of nightly use to help realign the circadian rhythm — and then pulling back to use as needed. A cluster might make sense for a few weeks after travel, during a tough transition, or while the family works on behavioral changes.

If a child needs melatonin every night for months, that’s a signal to dig deeper. “That tells me that there’s something likely going on underneath that’s not being addressed,” Dr. Nahmias says.

Side effects and safety

Melatonin is generally well tolerated, but knowing the possible side effects can help you catch problems early. The most common is grogginess the next morning. Others include irritability, headaches, dizziness, stomach upset, and — in toddlers and younger children — increased bedwetting. Some children may also experience vivid dreams or nightmares, though these tend to be mild.

Check in with your child’s pediatrician if side effects appear, your child needs melatonin frequently or for more than a short period, the dose keeps creeping up, sleep problems get worse, or if you notice signs of anxiety, depression, or ADHD that might be driving their sleep struggles.

One important safety note: melatonin gummies look like candy, and Dr. Owens describes an “astronomical increase” in calls to poison control centers and emergency room visits related to melatonin in children, largely due to accidental ingestion. Store melatonin — especially gummies — like any other medication: out of reach, ideally in a locked cabinet. Never present them to children as a treat.

A bigger concern: what’s actually in the bottle

Melatonin isn’t tightly regulated in the United States, which means the dose on the label may not match what’s actually in the product. Studies have found that 22 out of 25 over-the-counter melatonin gummies were labeled inaccurately, with some containing far more melatonin than advertised.

Dr. Owens describes the variability as “huge” and says she was genuinely shocked by the findings. When shopping, look for products with a USP Verified mark. USP (United States Pharmacopeia) is an independent nonprofit that tests supplements to confirm the product contains what the label says, in the correct amount, and without harmful contaminants.

Melatonin for kids with ADHD or autism

There’s solid evidence that melatonin can benefit children with neurodevelopmental conditions, particularly autism and ADHD, who are more likely to have disrupted sleep-wake cycles. “There is a pretty robust literature supporting efficacy, without a lot of side effects,” Dr. Owens says about children on the autism spectrum.

But Dr. Nahmias encourages parents of kids with autism or ADHD to take a closer look at bedtime routines before turning to melatonin. “Both of those populations of kids do best when there is structure put into their day,” he says. He recommends having a posted list of the sleep routine that a child needs to accomplish as a helpful visual reminder that will start to become second nature as it is built into their evening.

If getting to sleep is still an issue, trying melatonin makes sense. But for kids with autism and ADHD, it may take more time to see an effect. “It can be helpful to give it a bit longer to re-right the sleep cycle,” Dr. Nahmias says. “Trying it for two to three months may be more beneficial than just a few weeks.”

 Many neurodivergent kids may also need to stay on melatonin longer than neurotypical children. “This makes it absolutely imperative that administration of melatonin for these children is under the supervision of a health professional who can monitor efficacy and side effects, and recommend periodic ‘off-drug holidays,’” Dr. Owens says. The goal is to get sleep back on track and consistent for some time. Once that goal is achieved, Dr. Nahmias adds, “it is important that there be attempts to take breaks from the medication or try lower doses.”

When melatonin is not likely to help

Melatonin is often used in situations where it’s unlikely to make much difference. That’s not a criticism of parents — sleep deprivation is exhausting, and it’s natural to reach for something that seems gentle and accessible. But if the real issue is an inconsistent routine, untreated anxiety, or an unidentified medical problem, melatonin may only be a temporary solution. The real problem will persist and need diagnosis and treatment.

For younger children — kids under five, especially — sleep problems are almost always better addressed with changes in habits and routines rather than supplements. For kids under two, “there’s no reason to use melatonin… and really, honestly, under five, for the most part,” Dr. Owens says. At those ages, behavioral approaches almost always work better.

What to try before using melatonin

Small, consistent changes in sleep habits can make a real difference — and unlike a supplement, these strategies can help children build skills that support sleep for years to come. Dr. Nahmias focuses on what’s often called sleep hygiene: a consistent bedtime and wake time, a predictable wind-down routine, and a sleep environment that actually supports rest, like keeping the bedroom dark, cool, and quiet. “The bed is meant for one thing and one thing only, and that is for sleep,” he says, emphasizing no TV or cellphones before bed. Even small amounts of light can interfere with the body’s natural melatonin production.

He also suggests addressing anxiety, rumination, or bedtime fears directly. “Behavioral interventions, time and time again, have really been shown to be very effective,” Dr. Owens says. For younger children, that might mean learning to fall asleep without a parent in the room. For older kids and teens, it often means setting limits around devices and making sure the schedule they’re keeping is actually realistic.

Making a melatonin plan

Melatonin is a tool that works best with a plan behind it. Before starting, write down what problem you’re actually trying to solve. Is your child unable to fall asleep before 11pm? Waking during the night? Scared to sleep alone? Anxious about school?

A simple sleep log can make your conversation with your child’s doctor much more useful. For a week or two, track bedtime, approximate time asleep, any night wakings, morning wake time, screen use, and whether melatonin was used and, if so, at what dose. Dr. Owens calls sleep diaries “invaluable” because they reveal patterns that are nearly impossible to see when everyone’s tired and running on memory. That information helps you and your child’s doctor decide whether melatonin is worth trying, whether it’s working, and when it might be time to stop — keeping the focus not just on getting through tonight, but on helping your child build the sleep habits they’ll carry with them for years.

Frequently Asked Questions

Is melatonin safe for kids?

Melatonin is generally considered low risk and can be helpful for some children who have trouble falling asleep, especially when used short term and under a doctor’s guidance. But experts caution that there are still gaps in research about long-term use in kids, so it shouldn’t be treated as harmless or used casually without looking at underlying issues.

Can you OD on melatonin?

Accidental overuse can happen, especially because melatonin gummies may look like candy to young children. In recent years, there has been a major increase in poison control and ER visits related to accidental ingestion, so melatonin should always be stored like any medication — out of reach and ideally locked away.

Is melatonin bad for kids?

Melatonin is not inherently “bad” for kids, but it’s not the right solution for every sleep problem. If poor sleep is caused by anxiety, inconsistent routines, or a medical issue, melatonin may only mask the problem.

How much melatonin is safe for kids?

Experts recommend starting with the lowest effective dose. Some clinicians suggest starting with 1–2 milligrams for children ages four and up, and generally not exceeding 3 milligrams for kids ages 6–10 unless advised by a doctor.

The post Melatonin for Kids: Is It Safe? appeared first on Child Mind Institute.

Associations between serum tumor necrosis factor-alpha, hippocampal-prefrontal-ventricular volumes, and clinical profiles in schizophrenia: a biomarker and neuroimaging study in North Sumatera, Indonesia

IntroductionSchizophrenia is a neurodevelopmental disorder with systemic inflammation that is thought to play a role in its pathophysiology. The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α) has been reported to be dysregulated in individuals with schizophrenia, but its relationship with brain volume changes remains inconsistent. This study aimed to analyze differences in TNF-α levels and brain volume (hippocampus, prefrontal cortex, and lateral ventricles) and their correlations in schizophrenia patients compared to healthy controls.MethodsThis analytical cross-sectional investigation was conducted on 50 schizophrenia patients and 50 healthy Batak controls at the Prof. M. Ildrem Provincial Mental Hospital, Medan. Serum TNF-α levels were measured by ELISA, while brain structure volume was measured by 1.5 T MRI and analyzed using AnalyzePro software.ResultsTNF-α levels in the schizophrenia group were significantly lower (3.35 pg/dl) than in the control group (16.90 pg/dl). No significant differences in hippocampal and prefrontal cortex volume were found between the groups. However, lateral ventricle volume was significantly larger in schizophrenia. Correlation analysis showed a weak negative relationship between TNF-α and prefrontal cortex volume only in the schizophrenia group.DiscussionThe finding of low TNF-α in schizophrenia supports the complexity of immune dysfunction in schizophrenia, which may be influenced by medication or disease phase. Consistent ventricular enlargement reinforces previous neuroanatomical findings. The association of TNF-α with the prefrontal cortex only within the schizophrenia cohort indicates a specific interaction between inflammation and brain morphology in this patient population.ConclusionsThe findings support TNF-α dysregulation in schizophrenia, albeit at lower levels. Lateral ventricular enlargement was consistently found, while changes in hippocampal and prefrontal cortex volume may be more subtle in this population. The negative correlation between TNF-α and the prefrontal cortex in schizophrenia suggests a potential role for inflammation in the pathology of this brain region.

ESMR: a process framework for calibration dynamics across psychosomatic and psychiatric phenomena

The brain can be modeled as a generative system that predicts bodily and environmental input and reduces mismatch through updating and action. From this perspective, stress is treated not as prediction error per se, but as a condition in which mismatch persists without sufficient recalibration. Health is therefore defined not as the absence of symptoms, but as the preservation of recalibrability, whereas psychopathology is conceptualized as the progressive fixation of recalibration failure. This paper proposes ESMR as a four-layer, two-timescale process framework for comparing psychosomatic conditions, psychiatric disorders, and psychosis-level phenomena in terms of partially shared failures of recalibration rather than as a single disease continuum. ESMR distinguishes E (Embodied Constraints), S (Salience Calibration), M (Metacognitive Model Revision), and R (Reality-Grounding Interface) across learning (L) and development (D). Development is treated not merely as slower accumulation of prior learning, but as change in the biological, representational, and self-regulatory architecture that alters both what forms of recalibration are possible and the background conditions under which learning can be taken up. A central distinction is that M concerns whether corrective information can be converted into updating, whereas R concerns whether already understood correction can be adopted as self-relevant reality under embodied, practical, and interpersonal constraints, with downstream transfer treated as a consequence rather than part of the R core. The framework predicts layer-specific cross-signatures rather than a single undifferentiated burden effect and outlines a staged empirical program using framing, disconfirmation, reality-grounding, and embodied/interoceptive tasks. ESMR is offered as a revisable, clinically oriented intermediate framework rather than a completed computational model.

Lifestyle, psychological and demographic predictors of anxiety: insights from a large-scale survey and machine learning analysis

ObjectiveAnxiety is influenced by a combination of lifestyle, psychological, and demographic factors. This study aimed to evaluate these associations and explore the potential of machine learning in predicting anxiety severity.MethodsAnxiety levels were evaluated using a large survey-based dataset of 11, 000 adults alongside demographic, physiological, and psychological measures. Descriptive statistics and inferential analyses were conducted in IBM SPSS to identify associations between key variables. Several machine learning regression algorithms, including linear, regularized, and ensemble models, were implemented in Python to predict anxiety levels. Model performance was evaluated using standard error metrics.ResultsOur findings revealed significant associations of anxiety with stress and sleep duration, while demographic attributes such as family history of anxiety and occupation also influenced outcomes. Ensemble machine learning algorithms achieved superior performance compared to single and linear-model approaches. Feature importance analysis identified stress, sleep, and caffeine intake as top predictors of anxiety.ConclusionsThe integration of statistical approaches with machine learning applications highlights the multifactorial nature of anxiety and demonstrates the potential of predictive modeling in mental health care. Future research should emphasize longitudinal designs and the incorporation of biological and digital markers to enhance clinical applicability and prediction.

Aspects of Quality of Life in Interstitial Lung Disease: Pilot Observational Cross-Sectional Study in a Single Center

Background: Quality of life (QOL) is an important aspect of every chronic disease, including interstitial lung disease (ILD). QOL is perceived as a significant patient-centered outcome. Objective: This study aims to identify factors correlating with different aspects of QOL in patients with various ILDs. Methods: We recruited 57 participants hospitalized in a tertiary care clinical center to this pilot observational cross-sectional study. These included 22 patients with idiopathic interstitial pneumonia (IIP), 19 patients with connective tissue disease–associated ILD (CTD-ILD), and 16 patients with interstitial pneumonia with autoimmune features (IPAF). The Saint George’s Respiratory Questionnaire (SGRQ) and World Health Organization Quality of Life Questionnaire (WHOQOL-BREF) were used to assess QOL, and the Hospital Anxiety and Depression Scale – Modified Version (HADS-M) and Patient Health Questionnaire – 9 (PHQ-9) were used to evaluate depression severity. Functional parameters including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV), transfer lung capacity for carbon monoxide (TLCO), and 6-minute walk distance (6MWD) were assessed. Assessment of QOL was a secondary outcome measure in a multicenter prospective study aimed at determining the characteristics of Polish patients with interstitial pneumonia with autoimmune features. Results: In each study group, positive correlations existed between the WHOQOL-BREF physical domain score and FEV % predicted value (=.001) and TLCO % predicted value (=.03). Regardless of diagnosis, higher depression, anxiety, and aggression scores (ie, worse mental health) correlated negatively with multiple domains of QOL measured using the WHOQOL-BREF. Predictors of QOL aspects varied in each study group. In the IPAF group, the TLCO % predicted value was a predictor of QOL expressed as the SGRQ total score (=.005). In the CTD-ILD group, short 6MWD (<.001) and high HADS-M aggression score (=.01) correlated with low QOL (expressed as a high SGRQ total score). In the IIP group, 6MWD (=.002) and PHQ-9 scores (<.001) were predictors for SGRQ symptoms score. Gender-based differences were revealed: In all study groups, men had higher scores in the psychological, social, and environmental domains of the WHOQOL-BREF, indicating better QOL, without a statistically significant difference in the physical domain scores between genders. Diagnosis-based differences in the psychological aspects of QOL were also revealed: The QOL psychological domain scores were significantly lower in the CTD-ILD and IPAF groups than in the IIP group, indicating worse QOL (=.01). Conclusions: QOL is a multifaceted issue with various factors impacting its assessment. 6MWD, TLCO predicted value, and worse functional ability might specifically impact QoL in ILD. Mental health is an important aspect of QOL in the ILD population, as patients with a chronic, potentially life-limiting disease may be more prone to developing depression or anxiety. Assessment of QOL should be taken into account in clinical decision-making and research on chronic diseases, as this patient-related outcome may impact therapeutic decisions and patient compliance. Trial Registration: ClinicalTrials.gov NCT03870828; https://clinicaltrials.gov/study/NCT03870828

Impact of Restriction-Resumption Protocols on Mood and Anxiety in Healthy Adults: Randomized Controlled Trial

<strong>Background:</strong> Simple behavioral and cognitive actions can reduce symptoms of anxiety and depression. However, there is limited research investigating whether restricting those same actions increases symptoms and whether resuming those actions reduces symptoms. <strong>Objective:</strong> The primary aim was to examine the impact of restricting, then resuming (the “restriction-resumption protocol”), 5 groups of actions called the Things You Do (TYD), on symptoms of depression and anxiety. Participant satisfaction with life and perceptions of changes in behavior and mental health were also evaluated. <strong>Methods:</strong> In total, 70 adults were randomly allocated to an intervention group (IG) or a control group (CG). IG participants completed a 3-phase protocol over 8 weeks: a 2-week baseline period (phase A), 2 weeks of restricted TYD actions (phase B), and a 4-week resumption phase (phase C). CG participants were instructed to maintain their usual activities and routines. Primary outcomes included symptoms of depression (Patient Health Questionnaire–9), anxiety (Generalized Anxiety Disorder–7), and frequency of TYD actions. Secondary outcomes included satisfaction with life and perceived changes in mental well-being. Outcomes were measured weekly throughout the 8-week trial and again after the trial at week 9. <strong>Results:</strong> Scores on outcome measures did not differ between groups during phase A and after the trial. However, by the end of phase B, IG participants showed significantly increased symptoms of depression and anxiety compared to CG participants (<i>P</i>s&lt;.001). Large within-group effect sizes were observed on the Patient Health Questionnaire–9 and Generalized Anxiety Disorder–7 from baseline to the end of phase B (Cohen <i>d</i>&gt;1.8) and from phase B to after the trial (Cohen <i>d</i>&gt;1.9). Changes in satisfaction with life and evaluations of mental health corresponded with symptom changes. <strong>Conclusions:</strong> These findings demonstrate a relationship between the frequency of performing specific actions and symptoms of depression and anxiety. The restriction-resumption protocol has the potential to increase our understanding of causal mechanisms underlying common mental disorders and may lead to the development of new models of prevention and treatment. <strong>Trial Registration:</strong> Australian and New Zealand Clinical Trials Registry ACTRN12624001491550; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=388828&amp;isReview=true

Efficacy of a World Health Organization–Guided Self-Help Intervention for Reducing Psychological Distress in Afghan Refugees: Randomized Controlled Trial

Background: Common mental health disorders are highly prevalent among refugees. There is an urgent need to address the mental health burden in this population. Objective: This study tested the efficacy of an individually supported self-help stress-management intervention developed by the World Health Organization—Doing What Matters in Times of Stress (DWM)—in reducing psychological distress and improving functioning among refugees in Indonesia, a major transit country in the Asia-Pacific region. Methods: A single-blind randomized controlled trial with 303 Farsi-speaking refugees was conducted between June 2024 and June 2025. Participants with moderate to high psychological distress (Kessler Psychological Distress Scale [K10] score≥20) were randomly allocated to the facilitator-guided individual DWM condition (n=202) or a repeated assessment control condition (n=101). The primary outcome was psychological distress (K10 score) at the posttreatment assessment. Secondary outcomes were posttraumatic stress disorder symptoms, functional impairment, social functioning, and personally identified problems. Results: Intent-to-treat analysis indicated that participants in the DWM condition showed greater reductions in K10 scores than those in the repeated assessment control condition (posttreatment: =−.563, SE=0.124; <.001; Cohen =0.56; 1-month follow-up: =−.447, SE=0.140; =.002; Cohen =0.45). Similarly, those participants in the DWM condition reported greater improvements in posttraumatic stress disorder symptoms, well-being, social functioning, functional impairment, and personally identified psychological problems. No serious adverse events were reported. Conclusions: The findings provide the first evidence for the effectiveness of DWM in reducing psychological distress and improving overall functioning among urban refugees living in a transit setting. Individually supported self-help interventions such as DWM mayoffer an effective, feasible, and scalable approach to improving mental health for refugees. Trial Registration: ANZCTR ACTRN12624000609550; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=387637&isReview=true

CDKL5 deficiency results in atypical subregion-specific expression of perineuronal nets during mouse visual critical period

Perineuronal nets (PNNs) in the primary visual cortex (V1) are specialized extracellular matrix structures that form predominantly on parvalbumin+ GABAergic neurons, marking the closure of visual critical period plasticity. More recently, PNNs are used to characterize deficits in critical period plasticity in mouse models for neurodevelopmental disorders such as Rett syndrome, Fragile X syndrome, and CDKL5 deficiency disorder. Within the mouse V1, studies typically focus on the expression and function of PNNs within the binocular zone, though PNNs are expressed in other subregions of the V1. The expression and role of these PNNs in other subregions are unknown. Here, we performed a systematic whole V1 characterization of PNN expression using Wisteria floribunda agglutinin (WFA) staining, with hemisphere-, subregion-, and anatomical axes- specificity, using a null male mouse model for CDKL5 deficiency disorder during the visual critical period. Patients with CDKL5 deficiency disorder often exhibit cerebral cortical visual impairment, though the underlying mechanisms are unclear. Compared to wild-type controls, Cdkl5-null males show regional-specific changes in WFA expression; specifically, decreased all-PNNs in V1M and increased high-intensity PNNs in V1B at P30, and increased WFA pixel intensities in all three V1 subregions at P15, suggesting precocious altered PNN expression in the Cdkl5-null V1. In both genotypes, the binocular zone has significantly higher density of PNNs at both ages, compared to the monocular zone and the rostral V1. These results lay the groundwork to probe the roles for PNNs beyond the binocular zone and cumulatively suggest that, during visual critical period, subregion-specific variations in PNN expression may lead to functional consequences within the Cdkl5-null cortex.

Perceived stress and mental health in perimenopausal women: a serial mediation study of psychological distress and social support

BackgroundThe perimenopausal phase is associated with a significantly higher prevalence of mental health disorders in women, with stress perception emerging as a pivotal risk factor. However, the psychological and social mechanisms through which stress perception influences women’s mental health during this period remain to be fully elucidated. This study aims to use a stress process model to examine how social support mediates the link between stress perception and psychological symptom severity during perimenopause.MethodsA cross-sectional survey design was used, and 549 Chinese perimenopausal women were surveyed through face-to-face questionnaires. The survey employed the Chinese Perceived Stress Scale, Kessler Psychological Distress Scale, Perceived Social Support Scale, and Psychological symptom severity (BSRS-5) to evaluate participants’ psychological symptom severity. The researchers used SPSS 26.0 for related analyses, PROCESS macro software for regression analyses, and applied the Bootstrap method to assess mediating effects.ResultsThe findings of the study indicate that perceived stress, psychological distress, and psychological symptom severity (BSRS-5) are significantly and positively correlated, and perceived social support is significantly and negatively correlated with these variables (P < 0.01). The study reveals that perceived stress significantly increases psychological symptom severity scores(BSRS-5) (effect size=0.493, 59.60%) after adjusting for confounding variables. Additionally, psychological distress and perceived social support independently mediate this relationship (effect sizes=0.204, 24.67% and 0.101, 12.21%, respectively). Additionally, perceived stress indirectly affects psychological symptom severity(BSRS-5) through the chain-mediated mediating pathway of “psychological distress → perceived social support” (effect size = 0.030, percentage = 3.62%).ConclusionStress can directly increase psychological symptom severity in perimenopausal women and indirect effects can be observed through mediating factors such as psychological distress, perceived social support, and the chain-mediated relationship between these two elements. Thus, reducing symptom severity is essential for improving mental health. The study indicates that enhancing the mental health of this group requires a multifaceted approach. This approach should focus on the alleviation of psychological distress and the promotion of social support systems. This will effectively disrupt the cycle of stress and psychological distress.

The many manifestations of magical thinking: a systematic review

Magical thinking (MT) involves beliefs that thoughts or actions can influence events in unrealistic ways. While MT is integral to obsessive compulsive disorder, and reflected in the cognitive features of schizophrenia, it is observable across the general population in various forms. Given its prevalence and potential relevance to a range of psychiatric conditions, understanding more about what may predispose an individual to MT, and how it may in some cases culminate in psychological distress or dysfunction would be helpful. This paper reports a systematic review of studies investigating MT, encompassing both magical ideation and thought-action fusion specifically, across the disciplines of psychiatry and psychology, to shed further light on the likely predisposing factors and behavioural consequences of MT, its potential neurobiological underpinnings, and role in psychiatric symptomatology. After exclusions, 191 studies were identified that explored MT in association with a diverse array of secondary topics, from gambling compulsions to childhood trauma, within both clinical and non-clinical samples, across a range of cultural contexts. On an intra-individual level, MT demonstrates numerous cognitive and emotional correlates, and on a societal level it may influence both social custom and religious tradition. A synthesis of the available evidence uncovers unexplored relationships with social cognition and mental health, and future research investigating its emerging relationships with stress, mood and social connection, may uncover functions beyond those exhibited by a simple marker of psychopathology.